Using skin grafts to detect kidney transplant rejection

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of sentinel skin grafts from the same donor in diagnosing acute rejection of renal transplants. By monitoring patients who have undergone kidney transplantation, the study seeks to provide insights into the timing and methods for early immunization interventions. Participants will be closely followed post-surgery to assess the accuracy of skin grafts in indicating renal allograft rejection. The study involves multiple centers to gather diverse data and improve the reliability of findings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with end-stage renal disease undergoing renal transplantation;
2. 18-60 years old;
3. Postoperative follow-up points are complete (visit the hospital every week in the first month after surgery, every two weeks in 2-3 months, every four to six months, and every three months in 7-12 months. Follow up at any time when skin rejection is observed. The follow-up time may be adjusted when the condition changes);
4. The participants had good compliance, volunteered to participate in the test and signed the informed consent form.

Exclusion Criteria:

1. Untreated or disseminated malignant tumor;
2. Active period of infectious diseases;
3. Serious cardiovascular disease occurred recently;
4. Combined with other important organ failure;
5. History of mental illness or cognitive impairment;

Where it's running

• Xijing Hospital, Ari Force Medical University
  Xi'an, Shannxi, China Recruiting
• First Affiliated Hospital, School of Medicine, Zhejiang University
  Hangzhou, Zhejiang, China Recruiting
• Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Chenggang Yi, M.D.
• Email: cwar@163.com
• Phone: +8613567113534

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pelashield vs Xeroform for donor-site dressings in skin graft patients

  A randomized, patient-treated trial tests whether Pelashield, a new skin graft dressing, can better control pain and improve donor-site appearance compared with the standard Xeroform in split-thickness skin grafts.

  Recruiting Phase 4 Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT07734519

• Belimumab to mobilize memory B cells to help delistings for highly sensitized kidney transplant candidates

  A short belimumab course is being tested to see if it can reveal memory B cells that target donor HLAs, helping to decide which donors to exclude and potentially speed up getting a transplant for highly sensitized patients.

  Recruiting Phase 2 Leiden University Medical Center · Leiden · NCT07539857

• Frexalimab versus tacrolimus to prevent kidney transplant rejection

  This trial will test whether frexalimab injections given for up to five years work as well and are as safe as tacrolimus capsules at preventing rejection in adults getting their first kidney transplant who have low-to-moderate immune risk.

  Recruiting at 73 sites Phase 2/3 Sanofi · San Francisco, California and 72 other locations · NCT07412470

• Platelet aggregation for diagnosing acute kidney transplant rejection

  This study will test whether changes in platelet activation measured from blood can help detect acute rejection in adult kidney transplant recipients.

  Recruiting University Hospital, Martin · Martin · NCT07275541

• Donor-Derived Cell-Free DNA Test for Monitoring Kidney Transplants

  This test will try whether a blood-based donor-derived cell-free DNA (dd-cfDNA) assay can detect rejection in adults who have received a kidney transplant.

  Recruiting at 6 sites Insight Molecular Diagnostics · Los Angeles, California and 9 other locations · NCT07060716

• CRISPR-edited donor kidney transplant to reduce rejection risk

  This trial will see if donor kidneys edited with CRISPR to turn off key HLA genes can lower rejection in adults with end-stage kidney disease receiving transplants.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053462

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.